This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Alexion defends move to dismiss EmblemHealth's US claims over Soliris

( September 26, 2025, 19:54 GMT | Official Statement) -- MLex Summary: Alexion Pharmaceuticals defended its motion to dismiss EmblemHealth's US antitrust claims over the unlawful delay of biosimilar competition for Soliris, saying Emblem's claims over Alexion's patent litigation against Amgen and Samsung fail to allege a reverse-payment claim as to either settlement, nor sham litigation as to Amgen. Emblem also fails to cite any governing law that would support its claim that end payers have standing to allege Walker Process claims, but cases addressing the issue "consistently hold that indirect purchasers do not have standing to assert Walker Process claims because they are too remote from the alleged patent fraud," Alexion said in its reply supporting dismissal filed to the US District of Massachusetts.See attached document: ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections